{"id":"https://openalex.org/W1000000251","doi":"https://doi.org/10.1007/978-1-4684-9001-5_4","title":"Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin\u2019S Disease","display_name":"Antitumor Effects of Six Ricin A-Chain Immunotoxins of Potential Use in the Treatment of Hodgkin\u2019S Disease","publication_year":1990,"publication_date":"1990-01-01","ids":{"openalex":"https://openalex.org/W1000000251","doi":"https://doi.org/10.1007/978-1-4684-9001-5_4","mag":"1000000251"},"language":"en","primary_location":{"id":"doi:10.1007/978-1-4684-9001-5_4","doi":"https://doi.org/10.1007/978-1-4684-9001-5_4","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-1-4684-9001-5_4","pdf_url":null,"source":{"id":"https://openalex.org/S4306463937","display_name":"Springer eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeting of Drugs 2","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W4253035830","display_name":"Targeting of Drugs 2"},"type":"book-chapter","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057387418","display_name":"Andreas Engert","orcid":"https://orcid.org/0000-0002-1890-1523","observed_orcids":["https://orcid.org/0000-0002-1890-1523"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andreas Engert","raw_affiliation_strings":["Drug Targeting Laboratory, Imperial Cancer Research Fund, WC2A 3PX, Lincoln\u2019s Inn Fields, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Targeting Laboratory, Imperial Cancer Research Fund, WC2A 3PX, Lincoln\u2019s Inn Fields, London, UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111984641","display_name":"Philip E. Thorpe","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip Thorpe","raw_affiliation_strings":["Drug Targeting Laboratory, Imperial Cancer Research Fund, WC2A 3PX, Lincoln\u2019s Inn Fields, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Targeting Laboratory, Imperial Cancer Research Fund, WC2A 3PX, Lincoln\u2019s Inn Fields, London, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.26113861,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"39","last_page":"47"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hodgkin-lymphoma","display_name":"Hodgkin's disease","score":0.8899999856948853},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8539999723434448},{"id":"https://openalex.org/keywords/relapsed-hodgkin-lymphoma","display_name":"relapsed Hodgkin lymphoma","score":0.8809999823570251},{"id":"https://openalex.org/keywords/second-line-chemotherapy","display_name":"second-line chemotherapy","score":0.7559999823570251}],"concepts":[{"id":"https://openalex.org/C115085202","wikidata":"https://www.wikidata.org/wiki/Q425665","display_name":"Immunotoxin","level":4,"score":0.7654370665550232},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6731177568435669},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.6518447995185852},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.6250588893890381},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6238391399383545},{"id":"https://openalex.org/C2777200438","wikidata":"https://www.wikidata.org/wiki/Q408668","display_name":"Ricin","level":3,"score":0.6124357581138611},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5491735935211182},{"id":"https://openalex.org/C3018657049","wikidata":"https://www.wikidata.org/wiki/Q1595418","display_name":"Complete remission","level":3,"score":0.5188899636268616},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4104892611503601},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2676439881324768},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.11494490504264832},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.09761372208595276},{"id":"https://openalex.org/C2777367657","wikidata":"https://www.wikidata.org/wiki/Q184651","display_name":"Toxin","level":2,"score":0.08495140075683594},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.04886403679847717},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.04289740324020386}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1007/978-1-4684-9001-5_4","doi":"https://doi.org/10.1007/978-1-4684-9001-5_4","is_oa":false,"landing_page_url":"https://doi.org/10.1007/978-1-4684-9001-5_4","pdf_url":null,"source":{"id":"https://openalex.org/S4306463937","display_name":"Springer eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Targeting of Drugs 2","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.47999998927116394}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1521074246","https://openalex.org/W1528681389","https://openalex.org/W1530321233","https://openalex.org/W1554739819","https://openalex.org/W1584383434","https://openalex.org/W1941328144","https://openalex.org/W1973835842","https://openalex.org/W1983649348","https://openalex.org/W2045417135","https://openalex.org/W2061325970","https://openalex.org/W2080580789","https://openalex.org/W2118395503","https://openalex.org/W2124829257","https://openalex.org/W2132437826","https://openalex.org/W2151477771","https://openalex.org/W2166129740","https://openalex.org/W2269861991","https://openalex.org/W2282729572","https://openalex.org/W2314274799","https://openalex.org/W2470176307","https://openalex.org/W6810710458"],"related_works":["https://openalex.org/W2080233875","https://openalex.org/W2061945452","https://openalex.org/W2004916618","https://openalex.org/W1992001022","https://openalex.org/W984619883","https://openalex.org/W2607702712","https://openalex.org/W2399574493","https://openalex.org/W2020773272","https://openalex.org/W2164847107","https://openalex.org/W2335305356"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}